share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

Arcutis Biotherapeutics | 4:持股變動聲明-高管 Watanabe Todd Franklin
美股SEC公告 ·  2024/12/03 21:22

牛牛AI助理已提取核心訊息

Watanabe Todd Franklin completed a series of transactions involving Arcutis Biotherapeutics common stock. On 05/31/2024, he acquired 4,000 shares at $1.692 per share. Subsequently, on 11/30/2024, he purchased an additional 2,038 shares at $7.106 per share. The total number of shares acquired in these transactions was 6,038.Following these transactions, Watanabe's direct ownership of Arcutis Biotherapeutics shares increased to 838,430. The transactions were conducted as open market or private purchases. Additionally, Watanabe holds 231,140 shares indirectly through trusts and an LLC.These transactions reflect Watanabe's continued investment in Arcutis Biotherapeutics, with the latest acquisition completed on 11/30/2024. The transactions are now finalized, with no shares disposed of during this period.
Watanabe Todd Franklin completed a series of transactions involving Arcutis Biotherapeutics common stock. On 05/31/2024, he acquired 4,000 shares at $1.692 per share. Subsequently, on 11/30/2024, he purchased an additional 2,038 shares at $7.106 per share. The total number of shares acquired in these transactions was 6,038.Following these transactions, Watanabe's direct ownership of Arcutis Biotherapeutics shares increased to 838,430. The transactions were conducted as open market or private purchases. Additionally, Watanabe holds 231,140 shares indirectly through trusts and an LLC.These transactions reflect Watanabe's continued investment in Arcutis Biotherapeutics, with the latest acquisition completed on 11/30/2024. The transactions are now finalized, with no shares disposed of during this period.
渡邊託德·富蘭克林完成了一系列涉及Arcutis Biotherapeutics普通股的交易。2024年5月31日,他以每股1.692美元的價格收購了4,000股股票。隨後,他在2024年11月30日以每股7.106美元的價格又購買了2,038股股票。在這些交易中收購的股份總數爲6,038股。這些交易之後,渡邊對Arcutis Biotherapeutics股票的直接所有權增加到838,430股。這些交易以公開市場或私人購買的形式進行。此外,渡邊通過信託和有限責任公司間接持有231,140股股票。這些交易反映了渡邊對Arcutis Biotherapeutics的持續投資,最新的收購於2024年11月30日完成。交易現已完成,在此期間沒有出售任何股份。
渡邊託德·富蘭克林完成了一系列涉及Arcutis Biotherapeutics普通股的交易。2024年5月31日,他以每股1.692美元的價格收購了4,000股股票。隨後,他在2024年11月30日以每股7.106美元的價格又購買了2,038股股票。在這些交易中收購的股份總數爲6,038股。這些交易之後,渡邊對Arcutis Biotherapeutics股票的直接所有權增加到838,430股。這些交易以公開市場或私人購買的形式進行。此外,渡邊通過信託和有限責任公司間接持有231,140股股票。這些交易反映了渡邊對Arcutis Biotherapeutics的持續投資,最新的收購於2024年11月30日完成。交易現已完成,在此期間沒有出售任何股份。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。